BR112022026720A2 - Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas - Google Patents

Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas

Info

Publication number
BR112022026720A2
BR112022026720A2 BR112022026720A BR112022026720A BR112022026720A2 BR 112022026720 A2 BR112022026720 A2 BR 112022026720A2 BR 112022026720 A BR112022026720 A BR 112022026720A BR 112022026720 A BR112022026720 A BR 112022026720A BR 112022026720 A2 BR112022026720 A2 BR 112022026720A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
methods
recombinant
reduced protease
protease sensitivity
Prior art date
Application number
BR112022026720A
Other languages
English (en)
Inventor
Peng Li
A Shelke Sandip
Cao Lizhi
Original Assignee
Palleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palleon Pharmaceuticals Inc filed Critical Palleon Pharmaceuticals Inc
Publication of BR112022026720A2 publication Critical patent/BR112022026720A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

SIALIDASES RECOMBINANTES COM SENSIBILIDADE À PROTEASE REDUZIDA, PROTEÍNAS DE FUSÃO DE SIALIDASE E MÉTODOS DE USO DAS MESMAS. A presente invenção refere-se, de modo geral, às sialidases recombinantes (por exemplo, sialidases recombinantes que têm sensibilidade à protease reduzida), proteínas de fusão recombinantes e conjugados de anticorpo, e seu uso no tratamento de câncer.
BR112022026720A 2020-07-03 2021-07-02 Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas BR112022026720A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047989P 2020-07-03 2020-07-03
US202163134411P 2021-01-06 2021-01-06
PCT/US2021/040240 WO2022006492A2 (en) 2020-07-03 2021-07-02 Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same

Publications (1)

Publication Number Publication Date
BR112022026720A2 true BR112022026720A2 (pt) 2023-01-24

Family

ID=79317685

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026720A BR112022026720A2 (pt) 2020-07-03 2021-07-02 Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas

Country Status (11)

Country Link
US (1) US20230265406A1 (pt)
EP (1) EP4176056A2 (pt)
JP (1) JP2023532021A (pt)
KR (1) KR20230034320A (pt)
CN (1) CN115803047A (pt)
AU (1) AU2021299565A1 (pt)
BR (1) BR112022026720A2 (pt)
CA (1) CA3173145A1 (pt)
IL (1) IL299559A (pt)
MX (1) MX2023000243A (pt)
WO (1) WO2022006492A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735458A4 (en) 2018-01-03 2022-04-27 Palleon Pharmaceuticals Inc. RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014010943A (es) * 2012-03-16 2014-11-26 Genentech Inc Proteinas estabilizadas conformacionalmente de ingenieria.
CN107002110A (zh) * 2014-10-10 2017-08-01 恩细贝普有限公司 用具有改善的合成水解比的枯草杆菌蛋白酶变体的肽片段缩合和环化
EP3463447A4 (en) * 2016-06-03 2020-05-27 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUSES
EP3735458A4 (en) * 2018-01-03 2022-04-27 Palleon Pharmaceuticals Inc. RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
US20230265406A1 (en) 2023-08-24
WO2022006492A3 (en) 2022-02-17
JP2023532021A (ja) 2023-07-26
KR20230034320A (ko) 2023-03-09
MX2023000243A (es) 2023-03-03
CN115803047A (zh) 2023-03-14
AU2021299565A1 (en) 2023-02-02
WO2022006492A2 (en) 2022-01-06
CA3173145A1 (en) 2022-01-06
IL299559A (en) 2023-02-01
EP4176056A2 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
CO2021006092A2 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
MX2020007024A (es) Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
PE20210313A1 (es) Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
BR112021026789A2 (pt) Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas
BR112022026720A2 (pt) Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas
BR112015013319A2 (pt) lâmina cirúrgica ultrassônica
BR112018074759A2 (pt) artigo absorvente
BR112022022937A2 (pt) Proteínas de fusão estabilizadas de proteína de pico de coronavírus
DOP2021000145A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112023020123A2 (pt) Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstata
BR112022004575A2 (pt) Anticorpos de antígenos de vírus antioncolíticos e métodos de uso dos mesmos
BR112022013255A2 (pt) Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
BR112022020453A2 (pt) Anticorpos anti-cd98 e usos dos mesmos
CO2023016731A2 (es) Anticuerpos específicamente unidos a la proteína asm
NO20050216L (no) Steroidkonjugater samt fremstilling og anvendelse derav
Cheng et al. SPARC fusion protein induces cellular adhesive signaling
BR112021013096A2 (pt) Tratamento de doença de sjögren com proteínas de fusão de nuclease
BR112020027063A2 (pt) Tratamento de dor de cabeça com uso de anticorpos anti-cgrp
BR112023022079A2 (pt) Estrutura de carroceria de veículo, e, veículo
US10345301B2 (en) Method for treating infection of group A streptococcus
Sefiddashti et al. A 53 KDa glycan antigen of hydatid cyst wall may involve in evasion from host immune system
BR102020007149A8 (pt) Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca